March 8, 2018 8:31am

Set me a rule …

… Some investment firms think you’re so cool

The sequence of instructions can also end up being so cruel

… You’re a tool and a fuel for a “machine learning” recipe pool

As you alternate the spool to thread or unwind pricing accruals  

 

Pre-open indications: nine (9) targets

Q4 and FY17 results: Brainstorm Cell Therapy (BCLI) net loss for the year ended for FY17 was $4,95 M or -$0.26 per share compared to a net loss of $4,9M or $0.27 per share for FY16. Cash equivalents and short-term bank deposits were $7.75 M, CYTX after close and BLFS at 4:30 p.m.

 

If you had been subscribing, today’s events would not have been a surprise …

Slightly higher open expected

Dow futures are up +0.12% (+30 points) and NASDAQ futures are UP +0.56% (+39 points)

 

U.S. stock index futures rose slightly as investors awaited more news surrounding the U.S.' tariff plans.

Europe markets hovered around the flat line as investors awaited the latest interest rate decision from the European Central Bank (ECB)

Stocks in Asia rose after news of potential US tariff exemptions; China exports top forecasts

 

Issues to be faced at the open: tariffs continue to keep investors on edge.

Data docket: Ahead of the all-important nonfarm payrolls data due out on Friday, investors will be poring over initial claims data, due out at 8:30 a.m. ET on Thursday and the Quarterly Services Survey, due out at 10 a.m. ET.

 

 

Been where, done what …

RegMed, stem, gene and cell therapy sector’s record over 5 sessions (of 40 covered companies):

  • Wednesday closed POSITIVE with 9 decliners, 29 advancers and 2 flats;
  • Tuesday closed POSITIVE with 13 decliners, 22 advancers and 5 flats;
  • Monday closed POSITIVE with 12 decliners, 27 advancers and 1 flat:
  • Friday closed POSITIVE with 7 decliners, 30 advancers and 3 flats;
  • Thursday closed NEGATIVE with 24 decliners, 14 advancers and 2 flats;

 

 

Henry’omics:

From last night’s newsletter, “An overreaction. There is some instability but when isn’t there’s volatility? No panic selling as the upside impetus returns as sector confidence is at stake as I had stated, “Just might be a day to lighten the load, make a “buck” or come back and even buy a dip.”

As I had stated and reiterate, “Investors don’t seem nervous as algorithms detected the oversold! The issue will be the overbought aspect will they be fresh pickings by Fridays … I don’t see a correction but, a “bleed” of some value to those who have seen and felt the upside in the last four (4) sessions!”

 

 

Today’s indications:

  • The iShares Nasdaq Biotechnology (IBB) is indicating a POSITIVE +0.32% upside in Thursday’s pre-market;
  • The SPDR S&P Biotech ETF (XBI) is indicating a POSITIVE +0.18% upside in Thursday’s pre-market;
  • The Health Care Select Sector SPDR ETF (XLV) is indicating a POSITIVE +0.34% upside  in Thursday’s pre-open;
  • The iShares Russell 2000 (IWM) is NOT indicating a in Thursday’s pre-open

 

 

Companies in my headlights: Nine (9) …

  • Applied Genetic Technologies (AGTC)
  • bluebird bio (BLUE)
  • Caladrius Biosciences (CLBS)
  • Cellectis SA (CLLS)
  • Fate Therapeutics (FATE)
  • Regenxbio (RGNX)
  • Sangamo (SGMO)
  • Vericel (VCEL)
  • uniQure (QURE)

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.